Recently, Hangzhou MARIX Medical Technology Co., Ltd. (“MARIX”), a portfolio company of Hetang Venture Capital, announced the completion of its Series A financing round, raising tens of millions of RMB. This round was jointly invested by Hetang Venture Capital and the Anji Industrial Fund. The raised funds will continue to support clinical validation of MARIX’s core products, including coronary artery remodeling catheters. Meanwhile, the company will further increase its R&D investment, adhering to the concept of “intervention without implantation,” and launch more original medical device products tailored to the clinical treatment needs of vascular diseases.Founded in 2021 and headquartered in Hangzhou Future Sci-Tech City, MARIX is the first national high-tech enterprise in the industry dedicated to intravascular photochemical cross-linking technology. Adhering to the philosophy of "intervention without implantation," the company focuses on the research, development, and manufacturing of innovative medical devices in the field of vascular intervention. It has pioneered a Chinese solution based on the synergy between optics and vascular therapy, and established a product portfolio that includes coronary vessel remodeling catheters (NVS series), intracranial laser balloon dilation catheters (PBM series), and hemostatic occlusion devices.
Amid an increasingly stringent investment climate in the healthcare sector, MARIX continues to attract strong capital interest. Following tens of millions of RMB in angel funding in 2022 and tens of millions of RMB in Pre-A round financing in 2023, MARIX has once again secured investment from renowned institutions in its Series A round, fully demonstrating its robust strength and significant potential in the field of vascular intervention.
Meanwhile, MARIX is rapidly advancing multiple product lines. In June 2024, its intracranial balloon dilation catheter received NMPA approval; in January 2025, the coronary papillary balloon dilation catheter also successfully obtained NMPA certification, immediately ushering in a new chapter of commercial sales. Furthermore, core products including the coronary vascular remodeling catheter and the intracranial laser balloon dilation catheter have all entered the clinical follow-up stage, while the arterial closure hemostasis device has completed the supplemental submission process.These achievements not only highlight MARIX’s efficiency in product development and registration, but also lay the foundation for its continued R&D and strategic market expansion in the future.
In 2025, MARIX will continue to focus on the field of vascular intervention, committed to continuously launching innovative medical device products with significant clinical value, promoting the development of vascular intervention technology, and providing safer and more effective solutions for the treatment of patients with vascular diseases.
Regarding the Two Core Production Lines
1. NVS Series Products:Natural Vascular Scaffolding (NVS) therapy is a novel photochemical cross-linking technology that utilizes light-sensitive smart materials. Upon activation, these materials promote covalent bonding with amino acids in the extracellular matrix (ECM) proteins of the vessel wall, rapidly constructing a natural vascular micro-scaffold at the site of injured vascular tissue. This facilitates in situ self-healing and repair of the blood vessel, reduces elastic recoil, and leaves no foreign bodies after balloon withdrawal, truly achieving an "intervention without implantation" approach. This technology can be widely applied in various settings, including coronary, peripheral, and neurovascular interventions, as well as natural body lumens, offering patients a novel clinical therapeutic pathway for vascular injury repair.2. PBM Series Products: Photobiomodulation (Photobiomodulation, PBM) therapy utilizes biocompatible tissue-penetrating light to interact with intracellular chromophores, thereby modulating cellular and tissue responses. It has emerged as a promising non-invasive approach for tissue regeneration. PBM acts directly on cells to promote the adhesion and proliferation of endothelial cells, accelerate intimal repair, and reduce smooth muscle cell hyperplasia.For more details, please click [Read Original Article] below.This article is reprinted fromMARIXOfficial AccountAbout Hetang Venture CapitalEstablished in 2014 against the strategic backdrop of promoting the commercialization of scientific and technological achievements at Tsinghua University, Hetang Venture Capital is a professional investment management institution primarily focused on early-stage investments in technology-driven innovative enterprises. Hetang Venture Capital concentrates on key sectors including life sciences, medical devices, information technology, and advanced manufacturing. It maintains a long-term focus on investing in innovative companies with core hard technologies, while distinguishing itself through the incubation and investment of scientific and technological achievements derived from clinical experts at universities and top-tier hospitals. Currently, Hetang Venture Capital manages funds totaling nearly RMB 4 billion and has invested in over 90 projects. It supports scientists and entrepreneurs with significant research findings and technological innovations in translating their achievements into reality, facilitating “commercial transformation from 0 to 1,” while consistently adhering to the strategy of making early-stage investments in high-barrier “pioneering technologies.” Due to its outstanding performance, Hetang Venture Capital has received numerous honors, including being ranked among the “Top 50 Early-Stage Investment Institutions in China” by Zero2IPO Research and the “Top 50 Best Early-Stage Venture Capital Institutions in China” by CVSource.
